Focus on liver function abnormalities in patients with Turner syndrome: risk factors and evaluation of fibrosis risk
Abstract
CONTEXT: Liver function abnormalities (LFAs) have been described in patients with Turner syndrome (TS). Although a high risk of cirrhosis has been reported, there is a need to assess the severity of liver damage in a large cohort of adult patients with TS. OBJECTIVE: Evaluate the types of LFAs and their respective prevalence, search for their risk factors, and evaluate the severity of liver impairment by using a noninvasive fibrosis marker. METHODS: This was a monocentric retrospective cross-sectional study. Data were collected during a day hospital visit. The main outcome measures were liver enzymes (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase), FIB-4 score, liver ultrasound imaging, elastography, and liver biopsies, when available. RESULTS: 264 patients with TS were evaluated at a mean age of 31.15 ± 11.48 years. The overall prevalence of LFAs was 42.8%. The risk factors were age, body mass index, insulin resistance, and an X isochromosome (Xq). The mean FIB-4 sore of the entire cohort was 0.67 ± 0.41. Less than 10% of patients were at risk of developing fibrosis. Cirrhosis was observed in 2/19 liver biopsies. There was no significant difference in the prevalence of LFAs between premenopausal patients with natural cycles and those receiving hormone replacement therapy (P = .063). A multivariate analysis adjusted for age showed no statistically significant correlation between hormone replacement therapy and abnormal gamma-glutamyl transferase levels (P = .12). CONCLUSION: Patients with TS have a high prevalence of LFA. However, 10% are at high risk of developing fibrosis. The FIB-4 score is useful and should be part of the routine screening strategy. Longitudinal studies and better interactions with hepatologists should improve our knowledge of liver disease in patients with TS.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
LFA, defined as increased liver enzymes, are present in 40%-80% of patients with TS, with more recent studies on the high end of that estimate.
“LFA, defined as increased liver enzymes are present in 40%-80% of patients with TS, with more recent studies on the high end of that estimate.342-344,714,715”
From Clinical practice guidelines for the care of girls and women with Turner syndrome. (2024) · cites this paper as [715]
Recent studies suggest that FIB-4 scores are lower than expected in patients with TS, possibly reflecting that liver diseases are mild in most cases.
“Recent studies suggest that FIB-4 scores are lower than expected in patients with TS,714,715 possibly reflecting that liver diseases are mild in most cases.”
From Clinical practice guidelines for the care of girls and women with Turner syndrome. (2024) · cites this paper as [715]
Even young children with TS without risk factors have a higher prevalence of LFA.
“Risk factors for LFA are age, obesity, insulin resistance, and Xq isochromosome, however even young children with TS without risk factors have a higher prevalence of LFA.342-344,714,715”
From Clinical practice guidelines for the care of girls and women with Turner syndrome. (2024) · cites this paper as [715]
Risk factors for LFA in TS are age, obesity, insulin resistance, and Xq isochromosome.
“Risk factors for LFA are age, obesity, insulin resistance, and Xq isochromosome, however even young children with TS without risk factors have a higher prevalence of LFA.342-344,714,715”
From Clinical practice guidelines for the care of girls and women with Turner syndrome. (2024) · cites this paper as [715]
A recent study has shown that there is no difference in the prevalence of LFA between women with TS who have endogenous ovarian function compared to those receiving HRT.
“A recent study has shown that there is no difference in the prevalence of LFA between women with TS who have endogenous ovarian function compared to those receiving HRT.715”
From Clinical practice guidelines for the care of girls and women with Turner syndrome. (2024) · cites this paper as [715]
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · see citing works
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · see citing works
Vallet‐Pichard, A., Mallet, V. O., Nalpas, B., Verkarre, V., Nalpas, A., Dhalluin-Venier, V., Fontaine, H., & Pol, S. (2007) · Hepatology · doi:10.1002/hep.21669 · Cited by 2,085 · see citing works
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925 · see citing works
ACG clinical guideline: evaluation of abnormal liver chemistries
Kwo, P. Y., Cohen, S. M., & Lim, J. K. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.517 · Cited by 1,222 · see citing works
Mofrad, P., Contos, M., Haque, M., Sargeant, C. C., Fisher, R., Luketic, V., Sterling, R., Shiffman, M., Stravitz, R., & Sanyal, A. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,221 · see citing works
Whitfield, J. B. (2001) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/20014091084227 · Cited by 1,158 · see citing works
Gravholt, C. H., Andersen, N. H., Conway, G. S., Dekkers, O. M., Geffner, M. E., Klein, K. O., Lin, A. E., Mauras, N., Quigley, C. A., Rubin, K., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0430 · Cited by 1,101 · see citing works
Ferraioli, G., Wong, V. W., Castéra, L., Berzigotti, A., Sporea, I., Dietrich, C. F., Choi, B. I., Wilson, S. R., Kudo, M., & Barr, R. G. (2018) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2018.07.008 · Cited by 574 · see citing works
Gravholt, C. H., Juul, S., Naeraa, R. W., & Hansen, J. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00237-0 · Cited by 548 · see citing works
Xiao, G., Yang, J., & Yan, L. (2014) · Hepatology · doi:10.1002/hep.27382 · Cited by 512 · see citing works
Non-alcoholic fatty liver disease, obesity and the metabolic syndrome
Dietrich, P., & Hellerbrand, C. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.008 · Cited by 458 · see citing works
Mortality in women with Turner syndrome in Great Britain: a national cohort study
Schoemaker, M. J., Swerdlow, A. J., Higgins, C. D., Wright, A. F., & Jacobs, P. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1049 · Cited by 360 · see citing works
Estrogen replacement in Turner syndrome: literature review and practical considerations
Klein, K. O., Rosenfield, R. L., Santen, R. J., Gawlik, A. M., Backeljauw, P. F., Gravholt, C. H., Sas, T. C. J., & Mauras, N. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02183 · Cited by 151 · see citing works
Vascular involvement of the liver in Turner's syndrome
Roulot, D., Degott, C., Chazouillères, O., Oberti, F., Calès, P., Carbonell, N., Benferhat, S., Bresson-Hadni, S., & Valla, D. (2004) · Hepatology · doi:10.1002/hep.20026 · Cited by 143 · see citing works
X chromosome dosage of histone demethylase KDM5C determines sex differences in adiposity
Link, J. C., Wiese, C. B., Chen, X., Avetisyan, R., Ronquillo, E., Ma, F., Guo, X., Yao, J., Allison, M., Chen, Y.-D. I., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140223 · Cited by 121 · see citing works
Hormone replacement therapy may improve hepatic function in women with Turner's syndrome
Elsheikh, M., Hodgson, H. J. F., Wass, J. A. H., & Conway, G. S. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01321.x · Cited by 109 · see citing works
Liver involvement in Turner syndrome
Roulot, D. M. (2012) · Liver International · doi:10.1111/liv.12007 · Cited by 95 · see citing works
NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations
Niederseer, D., Wernly, B., Aigner, E. S., Stickel, F., & Datz, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030467 · Cited by 82 · see citing works
Koulouri, O., Ostberg, J., & Conway, G. S. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03203.x · Cited by 71 · see citing works
Elevated liver enzymes in Turner syndrome during a 5‐year follow‐up study
El‐Mansoury, M., Berntorp, K. E., Bryman, I., Hanson, C., Innala, E., Karlsson, A., & Landin‐Wilhelmsen, K. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03166.x · Cited by 63 · see citing works
Quantitative liver functions in Turner syndrome with and without hormone replacement therapy
Gravholt, C. H., Poulsen, H. E., Ott, P., Christiansen, J. S., & Vilstrup, H. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0070 · Cited by 56 · see citing works
Fiot, E., Zénaty, D., Boizeau, P., Haignere, J., Dos Santos, S., Léger, J., _, _., _, _., Carel, J. C., Cabrol, S., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0878 · Cited by 48 · see citing works
Self-citationYuan, Y., Shimizu, I., Shen, M., Aoyagi, E., Takenaka, H., Itagaki, T., Urata, M., Sannomiya, K., Kohno, N., Tamaki, K., et al. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.2200 · Cited by 46 · see citing works
Semmler, G., Wernly, S., Bachmayer, S., Leitner, I., Wernly, B., Egger, M., Schwenoha, L., Datz, L., Balcar, L., Semmler, M., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab339 · Cited by 44 · see citing works
Calanchini, M., Moolla, A., Tomlinson, J. W., Cobbold, J. F., Grossman, A., Fabbri, A., & Turner, H. E. (2018) · Clinical Endocrinology · doi:10.1111/cen.13811 · Cited by 41 · see citing works
Cameron-Pimblett, A., Davies, M. C., Burt, E., Talaulikar, V. S., La Rosa, C., King, T. F. J., & Conway, G. S. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02137 · Cited by 40 · see citing works
Viuff, M. H., Just, J., Brun, S., Dam, T. V., Hansen, M., Melgaard, L., Hougaard, D. M., Lappe, M., & Gravholt, C. H. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac167 · Cited by 35 · see citing works
Viuff, M. H., Stochholm, K., Grønbæk, H., Berglund, A., Juul, S., & Gravholt, C. H. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16277 · Cited by 30 · see citing works
Soria-Jasso, L. E., Cariño‐Cortés, R., Muñoz‐Pérez, V. M., Pérez‐Hernández, E., Pérez‐Hernández, N., & Fernández‐Martínez, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194694 · Cited by 28 · see citing works
Hepatic abnormalities in youth with Turner syndrome
Singh, I., Noel, G., Barker, J. M., Chatfield, K. C., Furniss, A., Khanna, A. D., Nokoff, N. J., Patel, S., Pyle, L., Nahata, L., et al. (2022) · Liver International · doi:10.1111/liv.15358 · Cited by 18 · see citing works
Cusi, K. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac186 · Cited by 2 · see citing works
Design and synthesis of ERα agonists: Effectively reduce lipid accumulation
Yang, J., Yao, W., Yang, H., Shen, Y., & Zhang, Y. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.1104249 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Clinical practice guidelines for the care of girls and women with Turner syndrome.
Gravholt, C. H., Andersen, N. H., Christin-Maitre, S., Davis, S. M., Duijnhouwer, A., Gawlik, A., Maciel-Guerra, A. T., Gutmark-Little, I., Fleischer, K., Hong, D., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae050 · Cited by 224 · see citing works
Self-citationThe Ovary–Liver Axis: Molecular Science and Epidemiology
Weiskirchen, R., & Lonardo, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136382 · Cited by 24 · see citing works
Jamalinia, M., Saeian, S., Nikkhoo, N., Nazerian, A., & Lankarani, K. B. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.131 · Cited by 17 · see citing works
Approach to the Patient With Turner Syndrome
Turner, H. E., Johannsen, E. B., Smyth, A., Orchard, E., & Gravholt, C. H. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf517 · Cited by 11 · see citing works
Zaegel, N., Brahimaj, R., Battaglia-Hsu, S.-F., Lamiral, Z., & Feigerlová, E. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae099 · Cited by 6 · see citing works
Meta‐Analysis: Liver Disease Burden and Associated Factors in Turner Syndrome
Jamalinia, M., Zare, F., Mantovani, A., Targher, G., & Lonardo, A. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70457 · Cited by 5 · see citing works
Porto-Sinusoidal Vascular Disorder: An Under-Recognized Liver Manifestation in Turner Syndrome
Siasiakou, S. M., Stoupi, E., Roumpou, A., Papanikolopoulou, A., Syrigos, N. K., TINIAKOS, D. G., & Peppa, Μ. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113979
La fonction ovarienne chez les femmes ayant un syndrome de Turner
Christin‐Maître, S. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.05.002
- Authors
- Bourcigaux, N., Dubost, E., Buzzi, J.-C., Donadille, B., Corpechot, C., Poujol-Robert, A., & Christin-Maitre, S.
- Affiliations
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Inserm (FR)
- Department of Hepatology, Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis (MIVB-H), French Network for Rare Liver Diseases in Children and Adults FILFOIE, European Reference Network (ERN) RARE-LIVER, Saint-Antoine Hospital & Research Center, Assistance Publique—Hôpitaux de Paris (APHP), Inserm & Sorbonne University , 75011 Paris , France
- Endocrine and Reproductive Medicine Unit, Center of Rare Endocrine Diseases of Growth and Development (CMERCD), FIRENDO, Endo ERN Hôpital Saint-Antoine, Sorbonne University , Assistance Publique–Hôpitaux de Paris, 75012 Paris , France
- Corresponding author
- Bourcigaux, Nathalie
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2023-03-10
- Volume
- 108
- Issue
- 9
- Pages
- 2255-2261
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W4323808234
- Cited by
- 8
- References
- 33
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 2
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- Turner syndrome, liver dysfunction, liver fibrosis, liver cirrhosis, FIB-4, non-invasive fibrosis markers, liver enzymes, gamma-glutamyl transferase, insulin resistance, hormone replacement therapy, liver ultrasound elastography, liver biopsy, risk factors
- MeSH terms
- Adult, Cross-Sectional Studies, gamma-Glutamyltransferase, Humans, Liver, Liver Cirrhosis, Liver Diseases, Retrospective Studies, Risk Factors, Turner Syndrome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review